Summary of COVID-19 deuremidevir studies

1. Fan et al., Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

1,296 patient deuremidevir early treatment RCT: 15% faster recovery (p=0.01) and 24% improved viral clearance (p=0.006).
RCT 1,369 patients with mild-to-moderate COVID-19 showing significantly faster time to sustained clinical symptom resolution (median 10.9 days vs 12.9 days) with VV116 compared to placebo. VV116 was given as 0.6g BID day 1 followed by 0.3g BID on days 2-5.
Nov 2023, The Lancet Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1473309923005777, https://c19p.org/fan3

2. Shen et al., An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants

136 patient deuremidevir early treatment study: 11% faster viral clearance (p=0.07).
Prospective 136 hospitalized mild to moderate COVID-19 patients in China, showing faster viral clearance with VV116 treatment. 60 patients received VV116 300mg twice daily for 5 days plus standard care, while 76 patients received only standard care. VV116 was generally safe, with only mild adverse events reported.
Jun 2022, Emerging Microbes & Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2078230, https://c19p.org/shen4